



Dedicated To Life

March 11, 2023

**BSE Limited**

1<sup>st</sup> Floor,  
P J Towers,  
Dalal Street,  
Mumbai-400001

**Code: 532321**

**National Stock Exchange of India Limited**

Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block,  
Bandra-Kurla Complex, Bandra (East),  
Mumbai-400051

**Code: Zyduslife**

**Re.:** Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated March 11, 2023 titled **“Zydus receives final approval from the USFDA for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg”**.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



## **Zydus receives final approval from the USFDA for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg**

*Ahmedabad, India, 11 March, 2023*

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg (USRLD: Zyprexa Zydus Orally Disintegrating Tablets).

Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg are used to treat certain mental/mood conditions (such as schizophrenia and bipolar disorder). Olanzapine tablets may also be used in combination with other medication to treat depression. These tablets belong to a class of drugs called as atypical antipsychotics and work by helping to restore the balance of certain natural substances in the brain. The products will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10 mg, 15 mg, and 20 mg had annual sales of USD 28.3 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 351 approvals and has so far filed over 440\* ANDAs since the commencement of the filing process in FY 2003-04.

(\*as of 31<sup>st</sup> December 2022)

\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878